Annals of Clinical Nephrology Open Access

  • Journal h-index: 2
  • Journal CiteScore: 0.09
  • Journal Impact Factor: 0.16
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Abstract

Characterized as the Time between Atazanavir Inception and the Beginning of Signs or Manifestations of Nephrolithiasis

Robert Medairos

The danger of nephrolithiasis related with atazanavir isn't very much described. The US Food and Drug Administration's Adverse Event Reporting System was looked for reports of nephrolithiasis in HIV-tainted patients taking an atazanavirbased routine. Thirty cases were recognized. Numerous patients required hospitalization for the board, including lithotripsy, ureteral stent addition, or endoscopic stone evacuation. A few instances of nephrolithiasis came about in atazanavir cessation. Medical services experts and patients should be educated that nephrolithiasis is a potential unfriendly occasion with atazanavir. The Adverse Event Reporting System (AERS) of the US Food and Drug Administration (FDA) is a deliberate detailing framework. This data set contains unconstrained reports produced by wellbeing experts, shoppers, and makers from the United States and different nations [3]. The AERS was looked for reports of nephrolithiasis in HIV-contaminated patients taking an atazanavir-based routine.

Published Date: 2022-01-03; Received Date: 2021-12-13